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Background: The Budd–Chiari syndrome (BCS) is hepatic venous
outflow obstruction. What is known about the syndrome is based
on small studies of prevalent cases.
Objective: To characterize the causes and treatment of incident
BCS.
Design: Consecutive case series of patients with incident BCS,
enrolled from October 2003 to October 2005 and followed until
May 2006.
Setting: Academic and nonacademic hospitals in France, Spain,
Italy, Great Britain, Germany, Belgium, the Netherlands, Portugal,
and Switzerland.
Patients: Persons older than 16 years with definite hepatic outflow
obstruction diagnosed by imaging. Persons with hepatic outflow
obstruction due to heart failure, sinusoidal obstruction syndrome,
cancer, or liver transplantation were excluded.
Measurements: Signs and symptoms; laboratory and imaging find-
ings; diagnosis; treatment; and overall, transplantation-free, and
intervention-free survival.
Results: 163 incident cases of BCS were identified. Median
follow-up was 17 months (range, 0.1 to 31 months). Most patients
(84%) had at least 1 thrombotic risk factor, and many (46%) had
more than 1; the most common was myeloproliferative disorders
(49% of 103 tested patients). Patients were mainly treated with
anticoagulation (140 patients [86%]), transjugular intrahepatic porto-
systemic shunting (56 patients [34%]), or liver transplantation (20
patients [12%]), and 80 patients (49%) were managed noninva-
sively. Only 3 patients underwent surgical shunting. The survival
rate was 87% (95% CI, 82% to 93%) at 1 year and 82% (CI,
75% to 88%) at 2 years.
Limitation: Treatment was not standardized across all centers, and
data on important clinical variables were missing for some patients.
Conclusion: Most patients with BCS have at least 1 thrombotic risk
factor, and many have more than 1; myeloproliferative disorders
are most common. One- and 2-year survival rates are good with
contemporary management, which includes noninvasive therapies
(anticoagulation and diuretics) and invasive techniques. Transjugular
intrahepatic portosystemic shunting seems to have replaced surgical
shunting as the most common invasive therapeutic procedure.
Primary Funding Source: Fifth Framework Programme of the
European Commission.
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The Budd–Chiari syndrome (BCS) is a rare but clinicallychallenging disorder defined as obstruction of hepatic
venous outflow anywhere from the small hepatic veins to
the suprahepatic inferior vena cava (1). In the Western
world, thrombosis is the most common cause. Classically, a
previously healthy young woman presents with sudden on-
set of abdominal pain, ascites, and hepatomegaly, but
many variations to this clinical presentation exist. Patients
frequently have an underlying thrombotic disorder. Stud-
ies have suggested that one quarter of patients have mul-
tiple thrombotic risk factors (2, 3). Therapeutic options
include medical treatments (anticoagulants and diuret-
ics) and invasive management (thrombolysis, percutane-
ous transluminal angioplasty, transjugular intrahepatic
portosystemic shunting [TIPS], surgical portosystemic
shunting, and orthotopic liver transplantation [OLT])
(4, 5).
The Budd–Chiari syndrome is uncommon, with an
incidence estimated at 1 in 2.5 million persons per year
(6), and current knowledge about its etiology and progno-
sis is based on small, older studies of prevalent cases. Thus,
what we know about the disease is influenced by survival
bias (patients must survive to be included as prevalent
cases) and does not incorporate experience with current
treatments and their effects (7–11). We therefore per-
formed a large prospective multicenter study of patients
with recently diagnosed BCS who were treated with con-
temporary therapies.
METHODS
Study Design
We studied a case series of consecutive patients with
incident BCS, identified in academic and large regional
hospitals in 9 European countries (France, Spain, Italy,
Great Britain, Germany, Belgium, the Netherlands, Portu-
gal, and Switzerland) between October 2003 and October
2005 and followed them until May 2006 (study closure);
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death; or for patients lost to follow-up, date of last visit. All
national and, if necessary, local ethics committees approved
the study, and all patients provided written informed con-
sent to participate.
We defined BCS as hepatic outflow obstruction re-
gardless of the cause or level of obstruction, which could
occur from the small hepatic veins to the entrance of the
inferior vena cava into the right atrium (1). Sinusoidal
obstruction syndrome (previously known as veno-occlusive
disease) was excluded from this definition. All consecutive
patients older than 16 years with newly diagnosed BCS
who met this case definition were enrolled if the evidence
for BCS was unambiguous and established by radiographic
imaging (ultrasonography, computed tomography, mag-
netic resonance imaging, or venography). Patients were ex-
cluded if outflow obstruction occurred in the setting of
heart failure, OLT, or hepatobiliary cancer.
Data Collection
To standardize patient management, all participating
centers received monitoring guidelines instructing provid-
ers what information to obtain when and advising them
about general indications for invasive procedures, such as
portosystemic shunting and OLT. Data were collected at
baseline; weeks 1 to 4; months 2, 3, 6, 9, 12, 18 and 24;
death; and significant clinical events, defined as clinical
deterioration (any new hospital admission or first develop-
ment or recurrence of massive ascites, spontaneous bacte-
rial peritonitis, hepatorenal syndrome, variceal bleeding, or
hepatic encephalopathy), new radiographic liver study, and
new BCS-related intervention. One investigator per coun-
try used a structured questionnaire to obtain all data from
standardized review of medical charts. For purposes of data
quality assessment, 1 investigator periodically reviewed and
monitored data. If data were missing or seemed erroneous,
the original charts were reviewed. Copies of the original
imaging studies were collected and scored by 1 radiologist
per country who had special expertise in vascular liver
disease.
Laboratory Testing
At diagnosis, plasma and DNA samples were obtained
according to a uniform protocol and sent to a central lab-
oratory (Hoˆpital Beaujon, Clichy, France) for standardized
thrombophilia assessment. Patients were screened for the
factor V G1691A mutation (factor V Leiden); the pro-
thrombin gene G20210A mutation; protein S, protein C
or antithrombin deficiency; myeloproliferative disorders
(MPDs) and the JAK2 V617F mutation; antiphospho-
lipid antibodies, hyperhomocystinemia, and the MTHFR
C677T mutation; paroxysmal nocturnal hemoglobinuria;
and Behc¸et disease. Because deficiencies of protein C and S
and antithrombin can be acquired through hepatocellular
dysfunction or use of anticoagulants or oral contraceptives,
a deficiency was considered hereditary if only 1 of the 3
proteins was deficient (isolated deficiency), the above-
mentioned drugs were not used, and the bilirubin level was
less than 2 times the upper limit of normal. In addition,
for protein S deficiency, patients could not also have the
factor V Leiden mutation or anticardiolipin IgG anti-
bodies, because these can influence protein S levels. An
expert who was not involved in data analysis reviewed
each case individually.
Statistical Analysis
Results are expressed as proportions for categorical
variables and as medians and ranges for continuous vari-
ables. Actuarial transplantation-free and intervention-free
survival rates were calculated by using the Kaplan–Meier
method. Variables that for historical or clinical reasons
were thought to be associated with invasive interventions
were entered individually and then together into a Cox
regression analysis to identify which were statistically sig-
nificant. The assumption of proportionality was verified by
taking all variables that were statistically significant in the
analysis and including them as time-dependent variables
(ln(variable)*time) in the final model (all P  0.10). Sta-
tistical significance was defined as a P value less than 0.05.
All statistical analyses were conducted with SPSS, version
14.0.0 (SPSS, Chicago, Illinois).
Role of the Funding Source
The EN-Vie project was financially supported by the
Fifth Framework Programme of the European Commis-
sion (contract “QLG1-CT-2002-01686) and public fund-
ing from GIS Maladies Rares (France 2001). The funding
agency had no role in the conduct of the study, the inter-
Context
Much of what is known about hepatic venous outflow
obstruction (the Budd–Chiari syndrome) comes from older
studies of previously diagnosed cases.
Contribution
Among 163 patients with newly diagnosed Budd-Chiari
syndrome who were prospectively followed at medical
centers in Europe, most had identifiable risk factors for
clot, most commonly myeloproliferative disorders. About
half of patients were managed noninvasively with diuretics
and anticoagulation, and half were managed with trans-
jugular shunting, recanalization, and liver transplantation;
survival rates were good.
Caution
Treatment and data collection were not standardized
across medical centers.
Implication
With contemporary management, survival among patients
with the Budd–Chiari syndrome is better than previously
described.
—The Editors
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pretation of the data, or the decision to submit the manu-
script for publication.
RESULTS
Sample
Table 1 shows baseline patient characteristics. Of 210
patients in 39 hospitals, 47 were excluded (date of diagno-
sis fell outside the study period [n  16]; diagnosis of BCS
not confirmed [n  14]; underlying cancer [n  7]; BCS
diagnosed only by liver biopsy [n  2]; secondary BCS in
the context of cirrhosis or liver tumor due to other under-
lying liver disease [n  6]; loss to follow-up after informed
consent was obtained [n  1]; and portal vein thrombosis
only, without involvement of the hepatic veins [n  1]),
leaving 163 eligible patients. The median age at diagnosis
was 38 years (range, 16 to 83 years); 93 patients (57%)
were female, and 87% were white. Median follow-up was
17.1 months (range, 0.1 to 31 months).
Clinical Features
Prominent clinical features were ascites (83%) and ab-
dominal pain (61%). One half of the patients had recent
onset of symptoms (1 month). In 5 patients, all of whom
were asymptomatic, BCS was found incidentally. Two
hundred twenty-seven imaging studies were performed to
establish the diagnosis; ultrasonography was most com-
monly used (88 patients [39%]), followed by computed
tomography (82 patients [36%]), magnetic resonance im-
aging (36 patients [16%]), and venography (21 patients
[9%]). The most prevalent feature on imaging was hepa-
tomegaly (67%). Hepatic outflow obstruction involved the
hepatic veins in 49% of patients, the inferior vena cava in
2%, and both in 49%. The inferior vena cava was occluded
by a membrane (thought to be a vestige of organized clot)
in only 2 patients. Concurrent obstruction in the portal
venous system was found in 30 patients (18%); locations
of obstruction included the portal (11 patients), superior
mesenteric (2 patients), and splenic veins (2 patients) or
combinations of the 3 (15 patients). Thirty-nine patients
(24%) underwent liver biopsy at diagnosis; histologic fea-
tures of sinusoidal congestion (25 patients [64%]), hepa-
tocellular necrosis (13 patients [33%]), and fibrosis (23
patients [59%]) were found, and significant heterogeneity
was often present within the same specimen. Evidence of
cirrhosis was present in 7 patients (18%).
Thrombotic Risk Factors
Table 2 summarizes thrombotic risk factors. Almost
all patients (160 [98%]) were screened for underlying
thrombotic disorders; 20 patients were anticoagulated at
the time of diagnosis before testing. At least 1 thrombo-
philic disorder was identified in 135 patients (84%), and
74 (46%) had more than 1 disorder. The most common
underlying disease was an MPD, which was found in 50
(49%) of the 103 patients who underwent bone marrow
biopsy (n  93), red cell mass measurement (n  29), or
Table 1. Patient Characteristics at Diagnosis
Characteristic Data
Clinical, n (%)*
Symptoms and signs
Ascites 135 (83)
Abdominal pain 99 (61)
Esophageal varices† 45 (58)
Hepatic encephalopathy 15 (9)
Type 1 hepatorenal
syndrome‡
12 (7)
Gastrointestinal bleeding 8 (5)
Duration of symptoms before
diagnosis
1 mo 82 (50)
1–6 mo 56 (34)
6 mo 23 (14)
Undetermined 2 (1)
Acuity of symptoms§
Acute 43 (26)
Chronic 33 (20)
Both 87 (53)
Laboratory
ALT/ULN ratio¶ 1.4 (0.3–294.4)
Albumin level, g/L 34 (17–51)
Bilirubin level
mol/L 31 (4–325)
mg/dL 1.8 (0.23–19.0)
Creatinine level
mol/L 80 (36–589)
mg/dL 0.91 (0.41–6.7)
Prothrombin time**
Seconds 18.1 (11.4–61.7)
International normalized ratio 1.4 (1.0–10.9)
Quick time, % 64 (7–100)
Radiographic, n (%)††
Caudate lobe hypertrophy 118 (72)
Hepatomegaly 109 (67)
Splenomegaly 85 (52)
Location of outflow obstruction
Hepatic veins 80 (49)
Inferior vena cava 4 (2)
Both 79 (49)
Number of hepatic veins
involved
1 15 (9)
2 15 (9)
3 129 (79)
Portal vein occlusion 30 (18)
Histologic‡‡
Sinusoidal congestion 25 (64)
Fibrosis 23 (59)
Hepatocellular necrosis 13 (33)
Cirrhosis 7 (18)
ALT  alanine aminotransferase; ULN  upper limit of normal.
* Data were available for all 163 patients in the sample.
† 77 patients underwent esophagogastroduodenoscopy.
‡ Defined as a decrease in creatinine clearance 50% to a value 20 mL/min or
an increase in serum creatinine level 2-fold to 221 mmol/L in 2 weeks.
§ By predefined criteria (11), “acute” is abdominal pain, ALT level 5 times the
ULN, and liver cell loss at biopsy (if available); “chronic” is previous symptoms or
hospitalizations, splenomegaly, atrophy or hypertrophy complex of liver lobes, and
centrilobular fibrosis or cirrhosis at biopsy (if available).
 Data are expressed as the median (range).
¶ ALT level divided by the laboratory-specific ULN. This ratio standardizes ex-
pression of elevation across medical centers.
** Measures exclude 20 patients who were anticoagulated at the time of diagnosis.
†† Data were available for all 163 patients. Patients may have had more than
1 imaging study. Findings are reported by detection according the following
hierarchy: magnetic resonance imaging, computed tomography, ultrasonogra-
phy, venography.
‡‡ Data were available for 39 patients.
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colony cultures (n  41). The JAK2 V617F mutation was
found in 35 of 121 tested patients (29%), of whom 27 had
a mutational load less than 50% and 4 had a mutational
load greater than 75%; mutational load could not be cal-
culated in 4 patients. Twenty-eight of the 35 JAK2-positive
patients (80%) already had features of MPD on bone mar-
row biopsy; the biopsy result was negative in 4 patients,
and biopsy was not performed in 3 patients.
The factor V Leiden mutation was found in 18 tested
patients (12%), and the prothrombin gene mutation was
found in 5 tested patients (3%). Many patients with the
factor V Leiden mutation had additional thrombotic risk
factors: oral contraceptive use (3 patients), oral contracep-
tive use plus MPD (2 patients) or antiphospholipid anti-
bodies (1 patient), MPD alone (3 patients), MPD plus
hyperhomocystinemia (1 patient) or antiphospholipid anti-
bodies (1 patient), protein C deficiency (1 patient), anti-
phospholipid antibodies (1 patient), and pregnancy (1 pa-
tient). Patients with prothrombin gene mutations also had
additional thrombotic risk factors (oral contraceptives plus
MPD [1 patient] or antiphospholipid antibodies [1 pa-
tient]) or hyperhomocystinemia [1 patient]; MPD alone
[1 patient]; or MPD, antiphospholipid antibodies, and
irritable bowel disease [1 patient]). Hyperhomocystinemia,
defined as elevated plasma homocysteine levels or homo-
zygosity for the MTHFR C677T mutation (genotype 677
TT), was detected in 28 tested patients (22%), of whom
79% had additional thrombotic risk factors. Among tested
patients, isolated protein C deficiency was present in 5
(4%), protein S deficiency in 3 (3%), and antithrombin
deficiency in 3 (3%).
Management
Eighty-three patients (51%) underwent an invasive in-
tervention, 80 (49%) were managed without an invasive
intervention, and 13 (8%) received no specific treatment
(Figure 1). Ten of the 13 untreated patients had no (n 
3) or mild (n  7) symptoms and nearly normal bilirubin
levels (median, 19 mol/L [range, 8 to 52 mol/L]). All of
these 10 patients survived and remained ascites-free at a
median follow-up of 22.7 months (range, 6.8 to 31.0
months). The remaining 3 untreated patients had severe
liver failure, and all of them died within 5 months (range,
1.6 to 4.4 months). The majority of patients received treat-
ment with anticoagulation (140 patients [86%]) and di-
uretics (100 patients [61%]). Twenty patients were already
receiving anticoagulation for a median of 27 days (range, 1
to 990 days) before diagnosis of BCS for previous throm-
botic events (n  11) or suspected but unconfirmed BCS
before the final diagnosis was made (n  9). Only 5 (8%)
anticoagulated patients developed variceal bleeding; all
cases were nonfatal.
Twenty-two patients underwent thrombolysis (n 
10) or percutaneous transluminal angioplasty (n  14) as
an initial invasive procedure. Immediate recanalization was
achieved in 4 (40%) patients undergoing thrombolysis and
8 (57%) of those undergoing percutaneous transluminal
angioplasty. Thirteen patients required subsequent TIPS,
and 1 patient deteriorated rapidly and needed OLT 2.8
months later.
Placement of TIPS was attempted in 64 patients
(39%) and was successful in 56 (34%). Main indications
for TIPS were refractory ascites (64%), liver failure (13%),
and variceal bleeding (5%). We observed no significant
differences in clinical variables between patients in whom
TIPS was successful and those in whom it was not, sug-
gesting that failure of placement was largely due to techni-
cal issues (data not shown). The approach of the TIPS
procedures was through the hepatic vein remnant in 49%
Table 2. Thrombotic Risk Factors*
Risk Factor Patients With
Risk Factor,
n/n (%)
Thrombophilia
Inherited†
Any inherited disorder 32/154 (21)
Factor V Leiden G1691A mutation 18/147 (12)
Prothrombin gene G20210A mutation 5/144 (3)
Protein C deficiency‡ 5/117 (4)
Protein S deficiency‡§ 3/108 (3)
Antithrombin deficiency‡ 3/112 (3)
Acquired†
Any acquired disorder 67/153 (44)
Antiphospholipid antibodies 37/150 (25)
Hyperhomocysteinemia 28/129 (22)
Paroxysmal nocturnal hemoglobinuria 15/77 (19)
Myeloproliferative disorder or JAK2 mutation¶ 56/143 (39)
Any myeloproliferative disorder 50/103 (49)
Polycythemia vera 27
Essential thrombocythemia 9
Idiopathic myelofibrosis 2
Unclassified 11
Occult** 1
JAK2 V617F mutation 35/121 (29)
Hormonal factors (women only)† 35/93 (38)
Oral contraceptive use 31/93 (33)
Pregnancy within 3 mo before diagnosis 6/93 (6)
Systemic† 37/163 (23)
Connective tissue disease 10
Inflammatory bowel disease 8
Behçet disease 4
Sarcoidosis 2
Vasculitis 1
Dehydration 5
Other†† 10
* Not all patients underwent every test.
† Patients were positive for at least 1 factor.
‡ Deficiency was diagnosed as nonacquired only if 1 protein was deficient, the
result occurred in the absence of use of anticoagulants or oral contraceptives, and
the patient did not have liver dysfunction (bilirubin level 2 times the upper limit
of normal).
§ Additional criteria for diagnosing protein S deficiency as nonacquired were ab-
sence of the factor V Leiden mutation and anticardiolipin IgG antibodies.
 Defined as elevated plasma homocysteine level (15 mol/L) or homozygosity
for the MTHFR C677T mutation.
¶ Diagnosis made by evidence of myeloproliferative disorder on bone marrow
biopsy, spontaneous colony formation on cultures, or presence of the JAK2
mutation.
** Negative biopsy result but positive culture result.
†† Intra-abdominal infection, sepsis, or spontaneous bacterial peritonitis.
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of patients and transcaval in 51%. Shunt dysfunction oc-
curred in 9 patients (18%) and was successfully treated by
TIPS revision in all cases. Polytetrafluoroethylene-covered
stents were used in 63% (35 patients), with a patency rate
of 85%. After TIPS, 3 patients (5%) required OLT.
In contrast to the liberal use of TIPS, surgical shunting
(all side-to-side portocaval) was performed in only 3 pa-
tients (2%). Thrombosis of the surgical shunt occurred in
1 patient, who died 2 months later. The second patient
who had surgical shunting continued to have refractory
ascites and underwent OLT after 9.8 months. The third
patient remained transplant-free.
Twenty patients (12%) underwent OLT. Indications
were fulminant or rapidly progressive liver failure (8 pa-
tients), absence of response on previous intervention (5
patients), rescue treatment for fulminant hepatic failure
after failed attempt of TIPS (2 patients), intractable
variceal bleeding (2 patients), refractory ascites (2 patients),
and the hepatopulmonary syndrome (1 patient). One pa-
tient died immediately after OLT because of multiorgan
failure (TIPS placement had failed in this patient), and 1
patient died 6.6 months after OLT because of ovarian sar-
coma that became evident only after the procedure. All 18
surviving patients were alive and symptom-free at a median
follow-up of 19 months after OLT (range, 1.1 to 30.2
months).
Survival and Prognostic Indicators
Fourteen patients were lost to follow-up after a median
of 17.4 months (range, 0.7 to 38.6 months), and 29 pa-
tients died a median of 5.5 months after diagnosis (range,
0.1 to 26.3 months). The main causes of death were liver
failure (8 patients), multiorgan failure (4 patients), and
gastrointestinal bleeding (2 patients). Median follow-up for
surviving patients was 19.3 months (range, 0.3 to 31
months). Overall survival rates were 90% (95% CI, 85%
to 94%) at 6 months, 87% (CI, 82% to 93%) at 12
months, and 82% (CI, 75% to 88%) at 24 months; the
Figure 1. Study flow diagram.
Patients with the Budd–Chiari syndrome (n = 163)
Medical treatment (n = 147)
Anticoagulation: 140
Diuretics: 100
Both: 93
Invasive treatment (n = 83)†
Medical treatment
only (n = 67)
Recanalization (n = 22)‡
PTA: 14
Thrombolysis: 10 
Both: 2
Decompression (n = 59)
TIPS: 56
Surgical PSS: 3
Proceeded to
decompression
(n = 13)
Proceeded to
recanalization
(n = 9)§
Proceeded
from TIPS to
OLT (n = 3)
Proceeded
from PSS to
OLT (n = 1)
No treatment (n = 13)
No treatment before
decompression (n = 3)*
OLT (n = 20)
Proceeded to
OLT (n = 1)
OLT  orthoptic liver transplantation; PSS  portosystemic shunt; PTA  percutaneous transluminal angioplasty; TIPS  transjugular intrahepatic
portosystemic shunt.
* 2 patients underwent TIPS, and 1 underwent surgical shunting.
† 22 patients proceeded directly to recanalization, 46 proceeded directly to decompression, and 15 proceeded directly to OLT.
‡ Patients can have had 1 procedure.
§ Revision of TIPS by recanalization procedures.
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respective OLT-free survival rates were 83% (CI, 77% to
88%), 77% (CI, 71% to 84%), and 68% (CI, 60% to
77%), and rates of survival without invasive intervention
were 52% (CI, 44% to 59%), 44% (CI, 36% to 52%), and
35% (CI, 26% to 44%) (Figure 2).
Univariate analyses revealed that patients with ascites
and hepatic encephalopathy; higher bilirubin, alanine ami-
notransferase, and creatinine levels and prothrombin time;
and lower albumin levels at diagnosis had higher rates of
invasive interventions (Table 3). In multivariable analyses,
ascites, male sex, and higher creatinine level were statisti-
cally significantly associated with invasive interventions.
DISCUSSION
This series of 163 incident cases of BCS in 9 western
European countries suggests that 1 or more thrombotic
risk factors underlie onset of the condition in most pa-
tients; that many patients can safely be managed with non-
invasive treatments, such as anticoagulation, and that most
who cannot can be managed with minimally invasive pro-
cedures, such as TIPS; and that survival is now better than
previously thought. These findings can be considered more
reliable than those of past studies, because our prospective
study design reduced the selection and information biases
common to previous retrospective studies. In addition, less
invasive management options for BCS are now more
readily available.
We found that most patients (84%) had an underlying
acquired or inherited thrombophilia and that 46% had 2
or more thrombotic risk factors; this proportion is almost
twice as high as previously reported (2, 3). This higher
frequency is probably attributable to the fact that we per-
formed a near-complete etiologic work-up; our findings
therefore show the appropriateness of a complete throm-
bophilia work-up in patients with BCS. The fact that 16%
of patients with BCS did not have a known prothrombotic
condition highlights the need to identify additional throm-
bogenic factors in the future, such as those in the fibrino-
lytic pathway, that might be clinically relevant.
Myeloproliferative disorders were the most prevalent
underlying conditions (49%), in line with previous findings
(12, 13). These disorders may not be clinically obvious in
patients with BCS because concurrent hypersplenism, oc-
cult gastrointestinal bleeding, and hemodilution can mask
peripheral blood abnormalities (14); bone marrow biopsies
are thus often needed when peripheral blood analysis is
nondiagnostic. The recently discovered JAK2 V617F mu-
tation has been found in 40% to 59% of patients with
BCS (12, 15, 16), which led some to propose that it could
be used as a screening test for MPDs. However, we found
the JAK2 mutation in only 29% of 121 tested patients. We
believe this discrepancy is largely attributable to selection
bias: All previous studies were retrospective, were con-
ducted exclusively in tertiary hepatology or hematology
Figure 2. Cumulative probability of overall survival, OLT-free survival, and intervention-free survival.
Patients at risk  0 3 6 9 12 15 18 21 24 27 30
Actuarial
survival, n 163 145 141 133 118 94 77 58 36 24 12
OLT-free
survival, n 163 135 130 120 103 80 65 47 28 19 10
Intervention-free
survival, n 163 92 82 70 59 46 36 25 15 8 5
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OLT  orthoptic liver transplantation.
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centers, and performed JAK2 testing on stored samples.
The diagnostic significance of the JAK2 mutation is yet to
be determined, but we believe that a hematologic work-up
for MPDs should be considered for all patients with BCS,
given the high prevalence of MPDs in this group.
The factor V Leiden and prothrombin gene mutations
are inherited thrombotic disorders classically associated
with BCS. The factor V Leiden mutation was prevalent in
12% of our predominantly white sample. This is lower
than the frequency of 22% to 31% reported in earlier
studies (2, 3, 17, 18). In comparison, the factor V Leiden
mutation is present in 12% to 19% of patients with deep
venous thrombosis (19, 20) and in 5% to 8% of the gen-
eral white population (21). The prevalence of the pro-
thrombin gene mutation (3% in our study vs. 2% in
healthy persons [22]) and hyperhomocystinemia (22) did
not exceed population frequencies. Selection of the sickest
patients in highly specialized centers probably accounts for
the discrepancy with older studies of BCS. Moreover, 78%
of patients with the factor V Leiden mutation and 100% of
those with prothrombin gene mutations had at least 1
other identifiable cause of BCS, indicating that the role of
these mutations is probably additive to other existing
thrombotic disorders.
Most of our patients received treatment with antico-
agulation (86%), followed by TIPS (34%), and only 3
patients received a surgical portosystemic shunt. This ob-
servation reflects how management of BCS has changed
over time. Before 2000, surgical shunting was the mainstay
of therapy (done in 50% to 68% of patients in earlier series
[10]). Transjugular intrahepatic portosystemic shunting
has overtaken surgical intervention in frequency, perhaps
because the feared complication of shunt occlusion has di-
minished with the newer polytetrafluorethylene-covered
stents, which provide excellent patency (23, 24). Although
evidence from randomized studies is lacking, we observed
good outcomes for patients with BCS who had TIPS and
therefore believe that TIPS should be the treatment of
choice for patients who do not respond to noninvasive
management and for those with refractory ascites and pro-
gressive liver dysfunction.
Nearly half of our patients were managed without a
radiologic or surgical therapeutic intervention. The time to
these interventions, which is used as a surrogate marker for
clinical deterioration, seemed to be determined by factors
related to patient survival (ascites, male sex, and higher
creatinine levels) (8, 10). These factors must be further
validated in future studies to establish their role in risk
stratification and clinical decision making.
We observed excellent short-term survival rates, which
were similar to and sometimes better than those observed
in earlier retrospective series, in which more aggressive in-
terventions (such as surgical shunting) were used (8, 10).
In part, this finding is explained by the fact that our study
was based on incident cases from both academic and com-
munity hospitals; as a result, our analysis was not restricted
to the sickest patients, as was the case in previous studies.
The fact that 86% of our patients received anticoagulation,
which is associated with the increased long-term survival
observed since 1985 (10), and the availability of effective
Table 3. Hazard for Invasive Intervention*
Predictor Univariate Cox Model Multivariate Cox Model
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
Age (per 10-y increase) 1.08 (0.95–1.22) 0.27 0.96 (0.81–1.12) 0.58
Sex
Male 1.38 (0.93–2.05) 0.11 1.69 (1.07–2.66) 0.024
Female 1.0 (reference) 1.0 (reference)
Ascites
Present 12.43 (3.92–39.36) 0.001 8.22 (1.91–35.36) 0.005
Absent 1.0 (reference) 1.0 (reference)
Hepatic encephalopathy
Present 3.89 (2.22–6.81) 0.001 1.87 (0.98–3.85) 0.089
Absent 1.0 (reference) 1.0 (reference)
Thrombophilia
Inherited and/or acquired 0.58 (0.34–0.99) 0.007 1.03 (0.50–2.12) 0.80
MPD or JAK2 mutation† 1.18 (0.70–1.98) 1.20 (0.61–2.35)
Other 1.0 (reference) 1.0 (reference)
Bilirubin level (per 10-mmol/L increase) 1.05 (1.02–1.09) 0.001 1.03 (0.98–1.08) 0.24
Albumin level (per 1-g/L increase) 0.95 (0.93–0.97) 0.001 0.97 (0.94–1.00) 0.078
Prothrombin time (per 1-unit increase in INR)‡ 1.23 (1.07–1.42) 0.001 1.02 (0.81–1.28) 0.88
ALT level (per 1-unit increase in ULN) 1.01 (1.01–1.02) 0.001 1.01 (1.00–1.01) 0.124
Creatinine level (per 10-mmol/L increase) 1.06 (1.04–1.08) 0.001 1.06 (1.02–1.09) 0.001
ALT  alanine aminotransferase; INR  international normalized ratio; MPD  myeloproliferative disorder; ULN  upper limit of normal.
*136 patients (83% of the total study population) had complete data on all variables and are included in the multivariate analysis. Of these, 80 underwent an invasive
intervention.
† Includes patients with only MPD and the JAK2 mutation (n  18) or in combination with inherited or acquired thrombophilia (n  36).
‡ If prothrombin time was expressed in terms other than in INR (e.g., seconds or Quick time), values were converted to INR assuming a normal value of 10 seconds. Patients
receiving anticoagulation at diagnosis (n  20) were excluded.
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and less invasive procedures (such as TIPS), which were
not commonly used in the past, probably also contribute to
the observed improvement in survival.
Our study has limitations. First, because the enroll-
ment period was long, follow-up time varied greatly. The
decision to extend the enrollment period at the expense of
the follow-up period to include a larger number of patients
was supported by data from several previous studies, which
showed that the majority of events (such as death, OLT,
and other treatments) occur in the first 6 months to 1 year
after diagnosis (8–10, 25). Extending the follow-up period
would probably not have resulted in gain of crucial infor-
mation. Second, most patients underwent a complete
work-up for thrombophilia, primarily because anticoagula-
tion given before or immediately after diagnosis limited
our ability to perform accurate tests in everyone. Third,
data on key clinical variables were missing for many pa-
tients. Finally, because the study was observational, treat-
ment allocation could not be standardized among all par-
ticipating centers.
In conclusion, our case series suggests that thrombo-
philias, and MPDs in particular, are very common in pa-
tients with BCS. On the basis of these findings, we believe
that a complete work-up for thrombophilia is warranted,
including screening for MPD, and that the work-up
should not stop after identification of a single cause, be-
cause almost half of patients have more than 1 underlying
disorder. Our study also suggests that patients with BCS
have excellent 1- and 2-year survival rates when they are
managed with anticoagulation and TIPS, with OLT as a
salvage procedure. Finally, surgical shunting, which was
the treatment of choice a decade ago, seems to have lost its
place in the contemporary management of BCS.
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